14-May-2019: The global psoriasis drugs market size is
expected to be valued at USD 21.11 billion by 2022, as per a new report by
Grand View Research, Inc., experiencing a CAGR of 9.4% during the forecast
period. Rising disease awareness, increasing number of reimbursement strategies
for biologics, and advanced diagnostic and technological tools are likely to
increase the adoption of psoriasis therapeutics.
Additionally, expanding base of
patients suffering from psoriasis is anticipated to fuel growth prospects. The
exact causative factors for psoriasis are undetermined; however, certain
genetic and environmental factors may trigger the disease onset. Most available
treatments aim to decelerate disease progression by stopping hyperproliferation
of keratinocyte.
Psoriasis can be classified
into five types: plaque, guttate, inverse, pustular, and erythrodermic. The
types vary in terms of site of disease and characterization of lesions.
Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent
type affecting patients all over the world.
Incidence rate of psoriasis has
witnessed a gradual rise over the years across various geographical locations.
This increase can be attributed to genetic and environmental triggers as well
as lifestyle changes. Rise in prevalence rates could also be associated with
declining response or developing resistance to therapies for disease control.
In
depth research report on Psoriasis Drugs Market
Further
key findings from the report suggest:
· Tumor
Necrosis Factor-inhibitors dominated the market in 2016 owing to its higher
usage by healthcare practitioners and easy availability
· TNF-inhibitors
are likely to lose market shares over the forecast period due to increasing
preference for IL-inhibitor therapy to conventional TNF-inhibitors
· Interleukin-inhibitors
is expected to register a lucrative CAGR of over 21.0% during the forecast
period owing to improved safety and efficacy profiles of Interleukin-inhibiting
drugs
· The U.S
is the dominant region in the psoriasis market in terms of revenue in 2016 due
to increasing number of patients seeking treatment and presence of
well-established healthcare services
· Japan
is expected to be the fastest growing region during the same period due to
growing awareness about the disease among the populace
· Some of
the key players in this industry are AbbVie Inc.; Amgen Inc.; Johnson &
Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celgene
Corporation; UCB; and Merck.
Grand View Research has
segmented the global psoriasis drugs market based on therapeutic class,
treatment, and region:
Therapeutic
Class Outlook (Revenue, USD Million, 2016 - 2022)
· Tumor
Necrosis Factor Inhibitor
· Interleukin
Inhibitors
· Others
Treatment
Outlook (Revenue, USD Million, 2016 - 2022)
· Topicals
· Systemic
· Biologics
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment